Sanyo claims H202 steralised incubator is industry first
Sanyo Biomedical and Environmental Solutions claims the H202 steralisation approach used by its Steisonic CxP MCO-19AIC(UVH) cell incubator system is an industry first and effective replacement for ethylene oxide (EtO).
Azopharma expands cytotoxics capacity
US contractor Azopharma has added new GMP quality cytotoxics and high-potency manufacturing capacity at its facility in Hollywood, South Florida in a bid to strengthen its position in the trial materials sector.
Sigpack says rotational toploader a revolution for vial handling
Sigpack Systems, a subsidiary of Bosch Packaging Technology, claims its new toploader unit will both improve the efficiency and cut the cost of handling delicate pharmaceutical packaging.
AMRI completes Budapest facility
AMRI (Albany Molecular Research, Inc) has completed construction of its R&D facility in Budapest, Hungary, which forms part of the company’s goal of transforming its European operations.
Norwich’s developmental expansion continues
Norwich is continuing to diversify and expand its offering by adding pilot scale production and capacity to develop high potency compounds.
Millipore’s Massachusetts Mobius plant open for business
Millipore has ramped up capacity for its Mobius range of single use bio-processing and manufacturing technologies with a new purpose built production facility in Danvers, Massachusetts.
Vetter expands secondary packaging capacity
German aseptic filling specialist Vetter has boosted packaging operations at its new facility in Ravensburg to meet growing demand for cost-effective secondary packaging services
Lonza’s GS system wins Elusys anthrax Ab contract
Swiss life sciences solutions firm Lonza has been contracted by US biotechnology group Elusys Therapeutics to produce Anthim, its late stage Ab candidate treatment for anthrax infection.
Patheon’s Q2 on track despite fall in demand
Contractor Patheon’s financial recovery is going well despite the current downturn in the outsourcing market, according to CEO Wes Wheeler.
Sanofi uses SCM for radiolabelled production
Sanofi-Aventis is using SCM Pharma’s aseptic fill/finish service for radiolabelled compounds to manufacture an oncology product that is in clinical trials.
Alfa hopes to make industrial chemistry an ART
Sweden’s Alfa Laval says ART PR49, its combined chemical reactor and heat transfer plate, improves the efficiency of chemical production and helps reduce energy costs.
FTC calls for biogenerics path and end of “pay for delay” deals
The US Federal Trade Commission (FTC) believes that an effective FOB approval pathway and laws preventing “pay-for-delay” deals are the only ways of reducing the cost of biologic drugs.
Biologics contracting worth $2.6bn this year, says HiTec
Demand for biopharmaceutical contract manufacturing will grow 16 per cent a year over the next five years, according to analysis by US market research group HighTech Business Decisions.
FDA revises ICH Q8 guidance
The FDA has revised its guidance on ICH Q8, adding an annex that clarifies the original document and adds the principles of quality by design (QbD).
Velesco adds clinical trial manufacturing to offering
US contractor Velesco Pharmaceutical Services has leased a new clinical trial materials manufacturing facility in Kalamazoo, Michigan, extending its range of preclinical and early trial development services.